Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 16, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 730,000 ordinary shares of 25 pence each.
- Purchase Price: 1,366.4039 pence per share.
- Treasury Holdings: 113,928,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,831,839,803 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 730,000 shares on September 16, 2005, increasing its Treasury stock holdings. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 730,000 share repurchase based on the disclosed price of 1,366.4039 pence.
- Confirm the updated total share count (5,831,839,803 in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share buyback authorization.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial metrics.